17th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Lupin under USFDA scanner over lapses at three facilities

Mumbai-based drug maker Lupin pharmaceuticals have come under US FDA’s glare after receiving two form 483s for its Pune and Nagpur facilities in October and a warning letter for its Tarapore facility recently.

Biocon Biologics set to acquire Viatris' biosimilar business

Biocon biologics a subsidiary of Biocon has completed all the regulatory requirements for the acquisition of Viatris’ biosimilars business and is working on the completion of an $800 million equity infusion as part of the deal.

USFDA to review baby formula manufacturing rules to avert bacterial illness

On Tuesday, the US health authority said that they are aiming to review the guidance and rules about manufacturing the infant formula as a part of its plan to prevent bacterial illness the same way as Abbot Laboratories products this year.

Large pharma firms leading in access-tomedicine strategies: Data

Access to Medicine Index 2022 which is a biyearly publication by the Access to Medicine Foundation, shows that all leading companies have access strategies for all late-stage research and development projects for the first time, which is benefitting the low and middleincome countries.

US regulatory authority sums up the inspection of Aurobindo pharma's unit 11

On November 16, during the stock regulatory filing, the company mentioned that US FDA concluded the inspection at its unit 11 and according to the US FDA website, the firm’s unit 11 has been classified as a Voluntary Action Indicated status.

Avanthi pharmaceutical college signs deal with medical documentation company

Avanthi Institute of Pharmaceutical Sciences signed an MOU (Memorandum of Understanding) with a medical documentation company, Aquity Solutions. According to the agreement, the company is going to provide jobs to the college students.

Novartis targets opthalmic, respiratory facilities for potential sell-offs after Sandoz

Amidst the course of restructuring of the company by the CEO, the company is analyzing various options including the sale of its ophthalmology and respiratory disease businesses as it lies outside the five major therapeutic areas they are trying to target, said a report by Bloomberg.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?